Is cannabis based medicine treat neuropathic pain?
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Cannabis-Based Medicine for Neuropathic Pain: Efficacy and Safety
Introduction to Neuropathic Pain and Cannabis-Based Medicine
Neuropathic pain, a chronic condition resulting from nerve damage, affects a significant portion of the population and is notoriously difficult to treat with conventional medications. Traditional treatments often provide limited relief and come with substantial side effects, prompting the exploration of alternative therapies such as cannabis-based medicines (CBM).
Efficacy of Cannabis-Based Medicines in Treating Neuropathic Pain
General Efficacy
Several studies have investigated the efficacy of cannabis-based medicines in alleviating neuropathic pain. A comprehensive review of 16 studies involving 1,750 participants found that cannabis-based medicines, including herbal cannabis, plant-derived THC, and synthetic cannabinoids, may provide modest pain relief. Specifically, 21% of participants achieved 50% or greater pain relief compared to 17% with placebo, indicating a small but significant benefit. Another meta-analysis of individual patient data from five randomized controlled trials suggested that inhaled cannabis could offer short-term pain relief for 1 in every 5 to 6 patients treated.
Specific Conditions
In patients with multiple sclerosis (MS) and spinal cord injury (SCI), a randomized, double-blinded, placebo-controlled trial found no significant difference in pain intensity between those treated with THC, CBD, or a combination of both, compared to placebo. However, other studies have shown that vaporized cannabis can significantly reduce pain intensity in patients with neuropathic pain related to spinal cord injury and disease, with minimal psychoactive side effects .
Safety and Tolerability of Cannabis-Based Medicines
Adverse Effects
The safety profile of cannabis-based medicines is a critical consideration. The review of 16 studies highlighted that more participants withdrew due to adverse events with cannabis-based medicines (10%) compared to placebo (5%). Common adverse effects included nervous system disorders and psychiatric disorders, occurring in 61% and 17% of participants, respectively. Another study noted that while psychoactive effects were minimal and well-tolerated, higher doses of cannabis could lead to acute cognitive effects, particularly affecting memory.
Long-Term Safety
The long-term safety of cannabis-based medicines remains uncertain due to the lack of long-term studies. Most research has focused on short-term outcomes, and there is a need for more extended trials to fully understand the long-term risks and benefits .
Conclusion
Cannabis-based medicines show potential in providing modest relief for chronic neuropathic pain, particularly in cases where traditional treatments have failed. However, the benefits must be weighed against the potential for adverse effects, and more research is needed to establish long-term safety and efficacy. As the medical community continues to explore these treatments, rigorous, well-designed clinical trials will be essential to provide robust evidence for their use in neuropathic pain management.
Sources and full results
Most relevant research papers on this topic